Skip to main content
Erschienen in: Clinical & Experimental Metastasis 6/2014

01.08.2014 | Research Paper

COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib

verfasst von: Emma Bell, Frida Ponthan, Claire Whitworth, Deborah A. Tweddle, John Lunec, Christopher P. F. Redfern

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

COX2 is an inducible cyclooxygenase implicated in the metastasis and migration of tumour cells. In neuroblastoma, COX2 expression has been detected in both cell lines and tumours. The treatment of neuroblastoma cells in vitro with celecoxib, a COX2 inhibitor, induces apoptosis. The aim of this study was to investigate the role of COX2 in neuroblastoma tumour biology by creating a cell line in which COX2 could be conditionally expressed. Xenograft studies showed that the conditional expression of COX2 enhanced tumour growth and malignancy. Elevated COX2 expression enhanced the proliferation and migration of neuroblastoma cells in vitro. However, elevated COX2 expression or variation between cell lines did not affect sensitivity to the COX2 inhibitor celecoxib, indicating that celecoxib does not promote cell death through COX2 inhibition. These data show that increased COX2 expression alone can enhance the tumorigenic properties of neuroblastoma cells; however, high levels of COX2 may not be a valid biomarker of sensitivity to non-steroidal anti-inflammatory drugs such as celecoxib.
Literatur
1.
Zurück zum Zitat Gasparini G et al (2003) Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4(10):605–615PubMedCrossRef Gasparini G et al (2003) Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 4(10):605–615PubMedCrossRef
2.
Zurück zum Zitat Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145–182PubMedCrossRef Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145–182PubMedCrossRef
3.
Zurück zum Zitat Singh B et al (2005) COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26(5):1393–1399PubMed Singh B et al (2005) COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 26(5):1393–1399PubMed
4.
Zurück zum Zitat Singh B et al (2007) COX-2 involvement in breast cancer metastasis to bone. Oncogene 26(26):3789–3796PubMedCrossRef Singh B et al (2007) COX-2 involvement in breast cancer metastasis to bone. Oncogene 26(26):3789–3796PubMedCrossRef
6.
Zurück zum Zitat Gupta GP et al (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446(7137):765–770PubMedCrossRef Gupta GP et al (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446(7137):765–770PubMedCrossRef
7.
Zurück zum Zitat Ren R et al (2007) Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses. Blood 109(7):2847–2853PubMedCentralPubMed Ren R et al (2007) Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses. Blood 109(7):2847–2853PubMedCentralPubMed
8.
Zurück zum Zitat Rodriguez C et al (2008) COX2 expression and Erk1/Erk2 activity mediate Cot-induced cell migration. Cell Signal 20(9):1625–1631PubMedCrossRef Rodriguez C et al (2008) COX2 expression and Erk1/Erk2 activity mediate Cot-induced cell migration. Cell Signal 20(9):1625–1631PubMedCrossRef
9.
Zurück zum Zitat Wu G et al (2006) Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 69(2):512–519PubMedCrossRef Wu G et al (2006) Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 69(2):512–519PubMedCrossRef
10.
Zurück zum Zitat Johnsen JI et al (2004) Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64(20):7210–7215PubMedCrossRef Johnsen JI et al (2004) Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res 64(20):7210–7215PubMedCrossRef
11.
Zurück zum Zitat Ara T et al (2009) Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 69(1):329–337PubMedCentralPubMedCrossRef Ara T et al (2009) Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 69(1):329–337PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Rasmuson A et al (2012) Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One 7(1):e29331PubMedCentralPubMedCrossRef Rasmuson A et al (2012) Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One 7(1):e29331PubMedCentralPubMedCrossRef
13.
14.
Zurück zum Zitat Ponthan F et al (2007) Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13(3):1036–1044PubMedCrossRef Ponthan F et al (2007) Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13(3):1036–1044PubMedCrossRef
15.
16.
Zurück zum Zitat Biedler JL et al (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38(11 Pt 1):3751–3757PubMed Biedler JL et al (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38(11 Pt 1):3751–3757PubMed
17.
Zurück zum Zitat Biedler JL, Spengler BA (1976) Metaphase chromosome anomaly: association with drug resistance and cell-specific products. Science 191(4223):185–187PubMedCrossRef Biedler JL, Spengler BA (1976) Metaphase chromosome anomaly: association with drug resistance and cell-specific products. Science 191(4223):185–187PubMedCrossRef
18.
Zurück zum Zitat Schleiermacher G et al (2003) Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet 141(1):32–42PubMedCrossRef Schleiermacher G et al (2003) Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet 141(1):32–42PubMedCrossRef
19.
Zurück zum Zitat Brodeur GM, Sekhon G, Goldstein MN (1977) Chromosomal aberrations in human neuroblastomas. Cancer 40(5):2256–2263PubMedCrossRef Brodeur GM, Sekhon G, Goldstein MN (1977) Chromosomal aberrations in human neuroblastomas. Cancer 40(5):2256–2263PubMedCrossRef
20.
Zurück zum Zitat Lovat PE et al (2002) GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res 62(18):5158–5167PubMed Lovat PE et al (2002) GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Res 62(18):5158–5167PubMed
21.
Zurück zum Zitat Demaison C et al (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13(7):803–813PubMedCrossRef Demaison C et al (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13(7):803–813PubMedCrossRef
22.
Zurück zum Zitat Bell E et al (2006) The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle 5(22):2639–2647PubMedCrossRef Bell E et al (2006) The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle 5(22):2639–2647PubMedCrossRef
23.
Zurück zum Zitat Scudiero DA et al (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48(17):4827–4833PubMed Scudiero DA et al (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48(17):4827–4833PubMed
24.
Zurück zum Zitat Team R (2008) Language and environment for statistical computing. R Foundation for Statistical Computing, Vienna Team R (2008) Language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
25.
Zurück zum Zitat Pinheiro J, Bates, D, DebRoy, S, Sarkar, D, R Core Team (2008) nlme: linear and non linear mixed effects models. R package version 3, pp 1–89 Pinheiro J, Bates, D, DebRoy, S, Sarkar, D, R Core Team (2008) nlme: linear and non linear mixed effects models. R package version 3, pp 1–89
26.
Zurück zum Zitat Pham DH et al (2008) Attenuation of leakiness in doxycycline-inducible expression via incorporation of 3′ AU-rich mRNA destabilizing elements. Biotechniques 45(2):155–162PubMedCrossRef Pham DH et al (2008) Attenuation of leakiness in doxycycline-inducible expression via incorporation of 3′ AU-rich mRNA destabilizing elements. Biotechniques 45(2):155–162PubMedCrossRef
27.
Zurück zum Zitat Sartelet H et al (2012) Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice. In vivo 26(1):19–29PubMed Sartelet H et al (2012) Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg null (NSG) mice. In vivo 26(1):19–29PubMed
28.
Zurück zum Zitat Zhu J et al (2004) From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64(12):4309–4318PubMedCrossRef Zhu J et al (2004) From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64(12):4309–4318PubMedCrossRef
29.
Zurück zum Zitat Ding H et al (2008) OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis. Int J Cancer 123(12):2923–2930PubMed Ding H et al (2008) OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis. Int J Cancer 123(12):2923–2930PubMed
30.
Zurück zum Zitat Schonthal AH (2007) Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Brit J Cancer 97(11):1465–1468PubMedCentralPubMedCrossRef Schonthal AH (2007) Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Brit J Cancer 97(11):1465–1468PubMedCentralPubMedCrossRef
31.
Metadaten
Titel
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib
verfasst von
Emma Bell
Frida Ponthan
Claire Whitworth
Deborah A. Tweddle
John Lunec
Christopher P. F. Redfern
Publikationsdatum
01.08.2014
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 6/2014
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-014-9656-3

Weitere Artikel der Ausgabe 6/2014

Clinical & Experimental Metastasis 6/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.